| # | Title | Journal | Year | Citations |
|---|
| 1 | NTRK gene fusions as novel targets of cancer therapy across multiple tumour types | ESMO Open | 2016 | 444 |
| 2 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial | ESMO Open | 2020 | 343 |
| 3 | Multiple primary tumours: challenges and approaches, a review | ESMO Open | 2017 | 334 |
| 4 | Mechanisms of resistance to EGFR-targeted drugs: lung cancer | ESMO Open | 2016 | 325 |
| 5 | Implementing TMB measurement in clinical practice: considerations on assay requirements | ESMO Open | 2019 | 257 |
| 6 | Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer | ESMO Open | 2017 | 248 |
| 7 | Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management | ESMO Open | 2018 | 197 |
| 8 | Cancer and liver cirrhosis: implications on prognosis and management | ESMO Open | 2016 | 194 |
| 9 | Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆ | ESMO Open | 2021 | 191 |
| 10 | Cardiotoxicity of immune checkpoint inhibitors | ESMO Open | 2017 | 186 |
| 11 | Global cancer control: responding to the growing burden, rising costs and inequalities in access | ESMO Open | 2018 | 169 |
| 12 | Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective | ESMO Open | 2020 | 161 |
| 13 | Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers | ESMO Open | 2016 | 152 |
| 14 | Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors | ESMO Open | 2019 | 151 |
| 15 | Biology of premature ageing in survivors of cancer | ESMO Open | 2017 | 148 |
| 16 | Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management | ESMO Open | 2019 | 140 |
| 17 | STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort | ESMO Open | 2020 | 139 |
| 18 | Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls | ESMO Open | 2016 | 126 |
| 19 | Hallmarks of glioblastoma: a systematic review | ESMO Open | 2016 | 122 |
| 20 | Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort | ESMO Open | 2016 | 119 |
| 21 | Targeting immune checkpoints in breast cancer: an update of early results | ESMO Open | 2017 | 118 |
| 22 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer | ESMO Open | 2020 | 113 |
| 23 | How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies | ESMO Open | 2018 | 112 |
| 24 | Activating HER2 mutations as emerging targets in multiple solid cancers | ESMO Open | 2017 | 109 |
| 25 | Challenge of cancer in the elderly | ESMO Open | 2016 | 107 |
| 26 | Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer | ESMO Open | 2017 | 105 |
| 27 | Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? | ESMO Open | 2018 | 105 |
| 28 | Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE) | ESMO Open | 2021 | 104 |
| 29 | Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers | ESMO Open | 2022 | 103 |
| 30 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer | ESMO Open | 2020 | 96 |
| 31 | Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers | ESMO Open | 2016 | 95 |
| 32 | The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy | ESMO Open | 2020 | 95 |
| 33 | Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury | ESMO Open | 2017 | 94 |
| 34 | Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial | ESMO Open | 2020 | 94 |
| 35 | Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN | ESMO Open | 2022 | 94 |
| 36 | First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update | ESMO Open | 2021 | 91 |
| 37 | Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials | ESMO Open | 2021 | 87 |
| 38 | Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer | ESMO Open | 2017 | 87 |
| 39 | Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy | ESMO Open | 2020 | 86 |
| 40 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence | ESMO Open | 2016 | 85 |
| 41 | How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere | ESMO Open | 2019 | 85 |
| 42 | Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature | ESMO Open | 2018 | 84 |
| 43 | New emerging targets in cancer immunotherapy: the role of LAG3 | ESMO Open | 2019 | 83 |
| 44 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 | ESMO Open | 2016 | 82 |
| 45 | New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis | ESMO Open | 2019 | 80 |
| 46 | Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer | ESMO Open | 2018 | 79 |
| 47 | How we treat patients with leptomeningeal metastases | ESMO Open | 2019 | 79 |
| 48 | New emerging targets in cancer immunotherapy: CD27 (TNFRSF7) | ESMO Open | 2019 | 78 |
| 49 | Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era | ESMO Open | 2021 | 78 |
| 50 | The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? | ESMO Open | 2021 | 77 |
